Aberrant embryonic development of the hypothalamus and/or pituitary gland in humans results in congenital hypopituitarism (CH). Transcription factor 7-like 1 (TCF7L1), an important regulator of the WNT/β-catenin signaling pathway, is expressed in the developing forebrain and pituitary gland, but its role during hypothalamopituitary (HP) axis formation or involvement in human CH remains elusive. Using a conditional genetic approach in the mouse, we first demonstrate that TCF7L1 is required in the prospective hypothalamus to maintain normal expression of the hypothalamic signals involved in the induction and subsequent expansion of Rathke's pouch progenitors. Next, we reveal that the function of TCF7L1 during HP axis development depends exclusively on the repressing activity of TCF7L1 and does not require its interaction with β-catenin. Finally, we report the identification of two independent missense variants in human TCF7L1, p.R92P and p.R400Q, in a cohort of patients with forebrain and/or pituitary defects. We demonstrate that these variants exhibit reduced repressing activity in vitro and in vivo relative to wild-type TCF7L1. Together, our data provide support for a conserved molecular function of TCF7L1 as a transcriptional repressor during HP axis development in mammals and identify variants in this transcription factor that are likely to contribute to the etiology of CH.
Aberrant embryonic development of the hypothalamus and/or pituitary gland in humans results in congenital hypopituitarism (CH). Transcription factor 7-like 1 (TCF7L1), an important regulator of the WNT/β-catenin signaling pathway, is expressed in the developing forebrain and pituitary gland, but its role during hypothalamopituitary (HP) axis formation or involvement in human CH remains elusive. Using a conditional genetic approach in the mouse, we first demonstrate that TCF7L1 is required in the prospective hypothalamus to maintain normal expression of the hypothalamic signals involved in the induction and subsequent expansion of Rathke's pouch progenitors. Next, we reveal that the function of TCF7L1 during HP axis development depends exclusively on the repressing activity of TCF7L1 and does not require its interaction with β-catenin. Finally, we report the identification of two independent missense variants in human TCF7L1, p.R92P and p.R400Q, in a cohort of patients with forebrain and/or pituitary defects. We demonstrate that these variants exhibit reduced repressing activity in vitro and in vivo relative to wild-type TCF7L1. Together, our data provide support for a conserved molecular function of TCF7L1 as a transcriptional repressor during HP axis development in mammals and identify variants in this transcription factor that are likely to contribute to the etiology of CH.
WNT pathway | pituitary | Tcf7l1 | septooptic dysplasia | hypopituitarism C ongenital hypopituitarism (CH) is a complex condition defined by the deficiency of one or more pituitary hormones and can be present in isolation or as part of a syndrome (1) (2) (3) . Septooptic dysplasia (SOD) is a rare form of CH (1 in 10,000) that manifests in conjunction with defects in the telencephalon (e.g., corpus callosum and septum pellucidum) and/or eyes (e.g., optic nerve hypoplasia) and is associated with high morbidity and occasional mortality (4) .
Abnormal embryonic development of the hypothalamo-pituitary (HP) axis is a major cause of CH. The pituitary gland, comprising the anterior and posterior lobes, is an organ of dual embryonic origin, and derives from oral and neural ectoderm, respectively. In the mouse at around 9.5 d postcoitum (dpc), secreted signals from the hypothalamic primordium such as fibroblast growth factor (FGF) 8, FGF10, bone morphogenetic protein 4 (BMP4), and sonic hedgehog (SHH) induce Rathke's pouch (RP), the primordium of the anterior pituitary (5, 6) . Upon specification, RP progenitors proliferate rapidly, exit the cell cycle, and activate the expression of cell fate commitment genes such as POU domain, class 1, transcription factor 1 [Pou1f1 (Pit1)], Tpit, and Sf1. This process culminates in the differentiation of all hormone-producing cells by the end of gestation (7, 8) : somatotrophs [growth hormone
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The relevance of transcription factor 7-like 1 (TCF7L1) during hypothalamo-pituitary (HP) axis development remains unknown. Using mouse genetics, we show that TCF7L1 acts as a transcriptional repressor to regulate the expression of the hypothalamic signals involved in pituitary formation. In addition, we screened a cohort of human patients with forebrain and/or pituitary defects and report two independent missense variants, p.R92P and p.R400Q, in human TCF7L1. Functional studies in vitro and rescue experiments in zebrafish mutants deficient for tcf7l1a and tcf7l1b show that the p.R92P and p.R400Q variants exhibit reduced repressing activity compared with wild-type TCF7L1. In summary, we identify TCF7L1 as a determinant for the establishment of HP axis development and as a potential candidate gene to be mutated in congenital hypopituitarism. (10) (11) (12) .
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Mutations in several developmental genes regulating HP development in the mouse have been identified in patients suffering from CH and SOD (4) . One of these is the homeobox gene Hesx1/HESX1, which acts as a transcriptional repressor of the WNT/β-catenin signaling pathway (13, 14) .
The stability of β-catenin, which is a strong transcriptional activator devoid of a DNA binding domain, is critical for normal WNT/β-catenin function (15) (16) (17) . In the absence of WNT ligands, β-catenin is phosphorylated by a destruction complex and degraded rendering the pathway inactive (18, 19) . The binding of WNT ligands leads to β-catenin dephosphorylation and stabilization (20, 21 ). β-Catenin can then translocate into the nucleus and interact with mainly, but not exclusively, members of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family to activate the expression of target genes (22, 23) . In mammals, TCF/ LEF factors include TCF7 (formerly TCF1), transcription factor 7-like 1 (TCF7L1) (formerly TCF3), TCF7L2 (formerly TCF4), and LEF1, which all bind the same consensus DNA motif 5′-(A/T) (A/T)CAAAG-3′ and have a β-catenin-interacting domain at the N terminus (24, 25) . It is believed that, in the absence of stable β-catenin, TCF/LEF factors can repress target genes of the pathway through interactions with corepressors (26, 27) , although cell context-specific functions have been demonstrated where specific factors are mostly required as either activators (28, 29) or repressors (30) (31) (32) (33) .
In the developing HP axis, this pathway coordinates proliferation of RP progenitors and differentiation of hormone-producing cells (34) (35) (36) (37) (38) (39) (40) (41) . TCF7L1 has been shown to play critical roles in maintenance of stem cell pluripotency (42, 43) , tissue homeostasis of the skin epithelia (44) , cell lineage determination during gastrulation (45, 46) , and brain development in vertebrates (47, 48) . However, the function of this important transcriptional factor during HP axis development has not been investigated to date. Moreover, despite the solid evidence demonstrating the critical function of the WNT/β-catenin pathway during HP axis development in the mouse, to date, mutations in components of this pathway have not been identified in patients with CH. In this study, we reveal that the β-catenin-independent repressor activity of TCF7L1 is required for normal HP axis formation in mice and humans.
Materials and Methods

Mice. The Hesx1
Cre/+ (49), Tcf7l1 flox/flox (44) , and Tcf7l1 ΔN/ΔN (33) have been previously described. We have previously shown that the Hesx1-Cre mouse line drives efficient recombination of loxP-flanked DNA in RP progenitors from 9.5 dpc (49, 50 Genomes (www.1000genomes.org), Single Nucleotide Polymorphism Database (dbSNP), Exome Variant Server (EVS), and the Exome Aggregation Consortium (ExAC) (comprising >61,000 genomes) Browser (exac. broadinstitute.org). Patients 1 and 2 were screened and found not to carry mutations in other relevant genes involved in CH and SOD, specifically patient 1 was screened for mutations in HESX1, CHD7, KAL1, PROKR2, FGFR1, and FGF8; and patient 2 was screened for mutations in HESX1, SOX3, KAL1, PROKR2, FGFR1, and FGF8.
In Situ Hybridization on Histological Sections. Histological processing of embryos and in situ hybridization on paraffin sections was performed as previously described (53, 54) . The antisense riboprobes used in this study [Gh, glycoprotein hormone α (Cga), Pomc1, Prop1, Lh, Tsh, Fgf10, Fgf8, Bmp4, LIM homeobox protein 3 (Lhx3), Bmp4, T-box 2 (Tbx2), T-box 3 (Tbx3), and Pit1] have been described (51, (53) (54) (55) . Human TCF7L1 riboprobe was generated using a full-length cDNA cloned into pCMV-Sport6 (SalI 5′, NotI 3′) (clone no. IRATp970D0681D, IMAGE no. 6141641; SourceBioscience).
Immunohistochemistry. Embryos were fixed in 4% (wt/vol) paraformaldehyde and processed for immunodetection as previously described (11, 51) . Detection of hormones was carried out using antibodies for (α-ACTH) (10C-CR1096M1), α-TSH (NHPP AFP-1274789), α-PRL (NHPP AFP-425-10-91), α-LH (NHPP AFP-C697071P), and α-FSH (AFP-7798-1289) (Developmental Studies Hybridoma Bank) at a 1:1,000 dilution. α-SHH (AF464; R&D Systems) and α-TCF7L1 (33) were used at a 1:100 dilution and signal amplified using the Tyramide Signal Amplification kit (NEL741001KT; Perkin-Elmer). α-Cleaved Caspase 3 was used at a 1:300 dilution (9661; Cell Signaling Technologies) and α-phosphorylated-histone H3 at a 1:1,000 dilution (06-570; Upstate). The mitotic index of pituitary periluminal progenitors represents the percentage fl/− developing pituitaries relative to control littermates at 13.5 dpc but not at 15.5 dpc. AP, anterior pituitary; BS, basisphenoid bone; Inf, infundibulum; OC, oropharyngeal cavity. Pictures are representative of seven embryos per genotype. ***P < 0.05 (one-way ANOVA). (Scale bar: H and P, 100 μm.) of proliferating cells (phosphorylated histone H3-positive cells) from total number of DAPI-positive nuclei. Anti-phosphorylated histone H3 (1:1,000) (rabbit polyclonal; Upstate) was used for this study.
Cell Transfection, Luciferase Assays, and Immunoblotting. HEK293T cells were grown in DMEM supplemented with 10% FBS. Two reporters were used to assess the repressing activity of human wild-type TCF7L1 and the p.R92P and p.R400Q variants: (i) the TOPflash reporter plasmid carrying six wild-type binding sites for the TCF/LEF1 factors upstream of the firefly luciferase gene; (ii) the LEF1-promoter-luc reporter, which contains a DNA fragment (−6713 to −1 bp) of the human LEF1 promoter inserted upstream of a luciferase reporter gene (33) . Approximately 250,000 cells were seeded per well of 24-well tissue culture plates and the following day subjected to DNA transfection. A total of 100 ng of TOPflash or 200 ng of LEF1-promoter-luc reporter were cotransfected with constructs expressing wild-type and mutant hTCF7L1 proteins (10 and 50 ng) and 80 ng of Renilla luciferase plasmid as internal control using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. The total amount of DNA was kept constant in all of the transfections by complementing with pBluescript plasmid up to 350 ng. Activation of the TOPflash reporter was achieved by culturing the cells in the presence of 10 μM SB216763 (Sigma), a potent GSK3-β inhibitor, resulting in the stabilization of β-catenin. The LEF1-promoter-luc was activated with 30 μM SB216763. The repressing activity of wild-type hTCF7L1 and the variants was assessed 48 h posttransfection using the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer's instructions. Total levels of repression caused by the hTCF7L1 p.R92P and p.R400Q proteins were represented as a percentage of the maximum repression caused by wild-type hTCF7L1. Experiments were repeated four times in triplicates and statistical analysis was done using one-way ANOVA with Tukey's post hoc analysis. Genotyping analysis of 9.5-18.5 dpc embryos from crosses between Hesx1
Cre/+ ;Tcf7l1 +/− and Tcf7l1 flox/flox showed a normal Mendelian distribution of genotypes, implying that the lack of Tcf7l1 in the Hesx1 cell lineage is not embryonic lethal (Table 1) . Hesx1
Cre/+ ; Tcf7l1 flox/− mutant embryos displayed variable degrees of anterior forebrain defects, including eye defects (i.e., microphthalmia or anophthalmia) and telencephalic abnormalities (i.e., small or absent telencephalic vesicles), as previously described (47) (Fig. S1C) . Additionally, we observed neural tube closure defects resulting in exencephaly in around 10% of these mutants (Fig. S1B) . Genotyping analyses of mice at 3 wk of age revealed no significant differences of the expected Mendelian ratios for the Hesx1
Cre/+ ; Tcf7l1 flox/− mutants compared with control littermates, but perinatal death was observed in some Hesx1
Cre/+ ;Tcf7l1 flox/− mice ( Table 1) . Most of the surviving mutants did not exhibit any gross morphological defects, but around 25% of these showed dwarfism with reduced size and weight compared with their littermates, suggesting a potential functional compromise of the HP axis (Fig. S1 A, D , and E). We observed unilateral microphthalmia with no compromise of the telencephalic vesicles in around 20% of the Hesx1
Cre/+ ; Tcf7l1 flox/+ embryos as previously reported (47) . Histological and in situ hybridization analyses of Hesx1
Cre/+ ; Tcf7l1 flox/− mutant and control embryos at 17.5 dpc revealed two clearly discernable pituitary phenotypes. (i) Group 1 embryos, ∼25% of the Hesx1
Cre/+ ;Tcf7l1 flox/− mutants, displayed severe morphological defects and ectopic pituitary tissue was often observed in the roof of the oropharyngeal cavity ( Fig. 1 A′′-H′′) . In these mutants, morphologically distinguishable posterior or intermediate lobes could not be observed. This phenotype was associated with severe forebrain defects. Hormone-producing cells were detected in these mutants, even in the ectopically located pituitary tissue. (ii) Group 2 embryos, accounting for ∼75% of Hesx1 ;Tcf7l1 flox/− mutants (n = 5) and 66,200 ± 7,585.62 for controls (n = 8). Although these differences did not reach statistical significance (P = 0.0584), the data suggest a trend toward mild hyperplasia in group 2 mutants.
Differentiation of hormone-producing cells occurred normally with no apparent differences between Hesx1
Cre/+ ;Tcf7l1 flox/− group 2 mutants and control embryos. The Sox2-positive stem cell compartment was analyzed in vitro by culturing dissociated cells in stem cell-promoting medium, which revealed no differences in clonogenic potential between group 2 mutants and controls (Fig. S2) . Similar morphological abnormalities, including hyperplasia, cleft bifurcations, and ectopically located pituitary tissue, were observed in Hesx1
Cre/+ ;Tcf7l1 flox/− mutants at 13.5 and 15.5 dpc. Nevertheless, expression of Lhx3, Pomc1, Prop1, and Pit1 at 13.5 dpc as well as Lhx3, Pomc1, Cga, and Pit1 at 15.5 dpc was detected in the developing pituitary of all mutants analyzed (Fig. 2 A-P) . Together, these analyses suggest that loss of Tcf7l1 in Hesx1-expressing cells leads to aberrant pituitary morphogenesis but normal cell differentiation in the majority of the embryos, with low penetrance of a phenotype characterized by ectopic pituitary tissue, possibly of anterior lobe identity, in the oropharyngeal cavity concomitant with defective terminal differentiation.
Abnormal Hypothalamic Signaling and Increased Proliferation of Rathke's Pouch Progenitors in Hesx1
Cre/+ ;Tcf7l1 flox/− Mutants. During early pituitary development, the synergistic expression of Bmp4, Fgf8, and Fgf10 within the developing hypothalamus is essential for the induction of Lhx3 in the region of the oral ectoderm fated to become RP (2). The expression domains of Fgf8, Fgf10, and Bmp4 in the hypothalamic anlage (Fig. 3 A-L) and of Lhx3 in the underlying RP (Fig. 3 M-P) were rostrally expanded in the Hesx1
Cre/+ ;Tcf7l1 flox/− mutants relative to controls at 9.5 dpc. Enlargement of the Lhx3-expression domain suggests the recruitment of additional oral ectoderm into RP epithelium, which may contribute to the hyperplasia observed at subsequent developmental stages. The expression of SHH, another critical signal required for normal RP development (58, 59) , in the preoptic area of the hypothalamus was shifted anteriorly and slightly reduced in the Hesx1
Cre/+ ;Tcf7l1 flox/− mutants in comparison with controls ( Fig. 4 I-L) . In agreement with this observation, the expression domains of Tbx3 and to a lesser extent Tbx2, which normally act as repressors of Shh expression in the hypothalamus (55), were rostrally shifted, thus invading the caudal region of the preoptic area, where SHH expression appears reduced (Fig. 4 A-H) .
Proliferation analysis revealed a mild but statistically significant increase in the mitotic index of RP periluminal progenitors in Hesx1
Cre/+ ;Tcf7l1 flox/− mutant pituitaries at 13.5 dpc (P < 0.05), but this increase was transient and not observed at 15.5 dpc (P > 0.05) (Fig. 2 Q-S) . This phenotype is entirely consistent with the deletion of Tcf7l1 in both the hypothalamus and RP in the Hesx1
Cre/+ ;Tcf7l1 flox/− mutant pituitaries (Fig. S3 C and D) . Caspase 3 immunostaining revealed the presence of a few apoptotic cells in the ventral regions of RP in both the mutant and control embryos (Fig. S3 A and B) . Together, these studies suggest that Tcf7l1 is required for proper patterning of the prospective hypothalamus and for establishment of the normal expression domains of critical hypothalamic signals involved in the induction and proliferation of RP progenitors.
TCF7L1 Functions as a Repressor During Normal Pituitary Organogenesis.
Next, we sought to assess whether the requirement of TCF7L1 within the developing hypothalamus and pituitary gland was dependent or independent of β-catenin. To achieve this, we used a recently generated mouse line (Tcf7l1
ΔN/ΔN
) expressing a TCF7L1 mutant protein lacking the β-catenin-interacting domain at the N terminus. This truncated form of TCF7L1 (TCF7L1 ΔN ) shows similar DNAbinding and -repressing activities to wild-type TCF7L1, but the mutant's interaction with β-catenin is abolished (33) .
In situ hybridization analysis revealed the absence of morphological defects in the pituitary gland and the normal expression of terminal differentiation markers (Gh, Pomc, Cga, Tsh, and Lh) in Tcf7l1 ΔN/ΔN mutants relative to control embryos at 18.5 dpc (Fig. 5 I-R) . Likewise, the expression domain of Fgf10 within the hypothalamus and Lhx3 in the developing RP were comparable between genotypes (Fig. 5 A-H) . Note that Tcf7l1 ΔN/ΔN mutants show a general developmental delay and are smaller than control littermates, which accounts for the slight size differences in the expression domains (Fig. 5 C and D) (33) . The absence of any apparent defects in Tcf7l1 ΔN/ΔN mutants demonstrates that TCF7L1 acts primarily as a transcriptional repressor within the developing hypothalamus and pituitary gland and that TCF7L1's function is independent of β-catenin. Additionally, these data imply that the defects observed in Hesx1
Cre/+ ; Tcf7l1 flox/− mutants are a consequence of the derepression of TCF7L1 transcriptional targets.
Variants in TCF7L1 Are Associated with Forebrain and Pituitary
Defects in Humans. The forebrain and pituitary defects observed in the Hesx1
Cre/+ ;Tcf7l1 flox/− mutants are very similar to those previously described in Hesx1-deficient embryos, suggesting that these transcriptional repressors may control the same genetic program (49, 54) . Because mutations in HESX1 have been associated with congenital hypopituitarism in humans, including SOD (60, 61), we hypothesized that mutations in TCF7L1 may also be implicated in these conditions. Indeed, in situ hybridization showed that TCF7L1 is expressed during human embryonic development within brain tissue, including the hypothalamus, and the developing pituitary gland (Fig. 6) .
To investigate this possibility, we screened a total of 215 patients with hypopituitarism including SOD for mutations in the TCF7L1 locus by Sanger sequencing. Two heterozygous sequence variants resulting in amino acid changes in highly conserved residues of TCF7L1 were identified in two unrelated patients (clinical details are presented in Table 2 and SI Text).
Patient 1 of Caucasian (Finnish; nonconsanguineous) descent, showing forebrain defects (i.e., partial agenesis of the corpus callosum, thin right optic tract, and thin anterior commissure), and normal pituitary function, carried a missense G-to-C sequence variant at position 275 (c.275G > C), which causes the substitution of arginine 92 by proline (p.R92P) (Fig. 7 A and B) . This variant was not identified in online databases (listed in Materials and Methods) or 392 additional Caucasian controls (including 200 healthy Finnish). The variant was inherited from the father and was also present in the paternal uncle, who were both asymptomatic.
Patient 2, of Pakistani (nonconsanguineous) descent, was diagnosed with classic SOD and showed small optic nerves and chiasm, an absent posterior pituitary, a very small anterior pituitary and absent septum pellucidum. The proband harbored a missense G-to-A sequence variant (c.1199G > A), resulting in an arginine to glutamine change at position 400 (p.R400Q) (Fig. 7 A  and B) . Although this variant was not identified in our healthy controls or the dbSNP or the Exome Sequencing Project (ESP) databases, the variant is present in 14 individuals in the ExAC database with an allelic frequency of 2.958 × e −5 in heterozygosity. The variant was inherited from the unaffected mother, and two unaffected siblings also carried the variant.
TCF7L1 p.R92P and p.R400Q Variants Show Impaired Repressing Activity in Vitro and in Vivo. We sought to assess the capacity of wild-type and hTCF7L1 p.R92P and p.R400Q proteins to repress WNT/ β-catenin-mediated transcriptional activation in vitro. We used two different reporters in transfected HEK293 cells cultured in the presence of a GSK3β inhibitor. Using the TOPflash reporter, the repressing activity of the TCF7L1 (p.R92P) variant was reduced by 34-40% (10 ng and 50 ng, respectively; P < 0.05) relative to wildtype TCF7L1 (Fig. 7C, left graph) . Likewise, the repressing activity of the TCF7L1 (p.R400Q) variant on the TOPflash reporter was diminished by 41-55% (10 ng and 50 ng, respectively; P < 0.05) compared with wild-type TCF7L1 (Fig. 7C, left graph) . A reduction of the transcriptional repressing activity of these variants was also observed when using the hLEF1-promoter-luc reporter [30% reduction for TCF7L1 (p.R92P) and 27% reduction for the TCF7L1 (p.R400Q) (P < 0.05); Fig. 7C , right graph]. In these transfection experiments, wild-type and mutant hTCF7L1 proteins were expressed at similar levels, as revealed by Western blot analysis using a specific anti-TCF7L1 antibody (Fig. 7D) . A potential molecular mechanism underlying the decreased repressing activity of the TCF7L1 (p.R92P) variant could be the increased phosphorylation of this protein by the Homeodomain-Interacting Protein Kinase 2 (HIPK2) compared with wild-type hTCF7L1 (Fig. S4 and SI Text) . No dominantnegative effects were observed in cotransfection experiments combining wild-type and hTCF7L1 p.R92P and p.R400Q variants (Fig. S5) .
Finally, to assess the repressing activities of the two variants in vivo, we took advantage of a zebrafish model with a lower gene dosage of the hTCF7L1 orthologs tcf7l1a and tcf7l1b. tcf7l1a −/− and tcf3l1b +/− single mutants show no phenotype, but tcf7l1a −/− ; tcf3l1b +/− double mutants exhibit an eyeless phenotype attributable to the ectopic activation of the Wnt/β-catenin signaling pathway and derepression of targets of this pathway in the forebrain (including the eye field) (30, 31). We injected double tcf7l1a −/− ;tcf7l1b +/− double mutant zebrafish embryos, which normally develop no eyes, with mRNA encoding either wild-type hTCF7L1 or the two variants identified, with the aim of determining the variants' ability to rescue the eyeless phenotype. Microinjection of wild-type hTCF7L1 mRNA fully rescued the eyeless phenotype of tcf7l1a −/− ;tcf3l1b +/− double mutants ( Fig.  8 ; n = 18 mutants, three independent experiments). However, only 64.5% (n = 31 mutants, three independent experiments) and 49.65% (n = 24 mutants, two independent experiments) of the eyeless tcf7l1a −/− ;tcf3l1b +/− double mutants were rescued by injection of mRNA encoding the hTCF7L1 p.R92P and p.R400Q variants, respectively (Fig. 8) . These results support the in vitro findings previously presented and add further evidence to the notion that the hTCF7L1 variants p.R92P and p.R400Q exhibit reduced repressing activity in vivo.
Discussion
In this study, we have provided genetic and molecular evidence demonstrating that the repressing activity of the transcription factor TCF7L1 is required for normal establishment of the HP axis in mice and humans. The pituitary defects of the Hesx1
Cre/+ ;Tcf7l1 flox/− mouse mutants are very similar to those observed in Hesx1 −/− embryos; increased proliferation leading to abnormal pituitary morphogenesis but overall normal terminal differentiation (14, 54) . We show the absence of mTCF7L1 protein in both the hypothalamus and the developing RP by 10.5 dpc in Hesx1
Cre/+ ;Tcf7l1 fl/− mutants, thus validating the genetic approach. Within the hypothalamus, we have revealed a critical role for mTCF7L1 in the regulation of anteroposterior patterning, because there is an overall anterior shift in the expression domains of caudal hypothalamic signals and markers (e.g., Fgf8, Fgf10, Bmp4, Tbx2, and Tbx3), which is concomitant with a reduction in SHH expression in the anterior hypothalamic area (Figs. 3 and 4) . This abnormal hypothalamic signaling results in the recruitment of additional ectoderm into RP, as detected by the rostral expansion in the Lhx3 expression domain and increased proliferation in the developing pituitary of Hesx1
Cre/+ ;Tcf7l1 fl/− mutants at 13.5 dpc. In addition, there may be a contribution to the phenotype attributable to the lack of TCF7l1 within RP, which we cannot rule out.
There is a marked variability of expressivity of the pituitary phenotype in Hesx1 Cre/+ ;Tcf7l1 fl/− mutants at 9.5 dpc show a lack of contact between the developing infundibulum and RP, which may contribute to the development of the ectopic pituitary in the roof of the oropharyngeal cavity. It is likely that this phenotypic variability observed from 13.5 dpc is brought about by the differential dysregulation of the hypothalamic signals normally involved in induction and proliferation of RP progenitors, an idea that is difficult to test experimentally.
Previously, we have shown that the cooperation between HESX1 and TCF7L1 is required to repress the activation of the WNT/β-catenin pathway in the anterior neural plate of zebrafish and mouse embryos (47) . Our data are in support of the idea that TCF7L1 acts as a repressor during normal pituitary development in mice. Functional studies in mice have demonstrated a temporally specific function of the WNT/β-catenin signaling pathway during pituitary organogenesis. This pathway must be repressed at early stages of pituitary development and activated from 14.5 dpc for normal differentiation of the Pou1f1-cell lineage (37) . In agreement with this notion, the permanent activation of the WNT/β-catenin pathway in RP progenitors at 9.5 dpc, by expression of a degradation-resistant form of β-catenin, results in severe pituitary hyperplasia during embryogenesis (50) . Mice deficient for Tcf7l2, a TCF/LEF factor shown to act as either an activator or a repressor depending on the cell context, show anterior pituitary hyperplasia but no defects in the differentiation of hormone-producing cells (41) mutants suggest that these factors are likely to act as transcriptional repressors of WNT/β-catenin pathway targets during HP axis development. Indeed, the expression of a mutant form of TCF7L1 unable to interact with β-catenin, but maintaining repressing activity does not lead to any hypothalamic or pituitary defects, demonstrating that TCF7L1 is required as a repressor (Fig. 5) .
Our data also provide evidence that the repressing activity of TCF7L1 is required for normal HP axis development in humans. Firstly, we show the expression of hTCF7L1 mRNA in the developing human embryo (Fig. 6) . Furthermore, we have identified two TCF7L1 variants, p.R92P and p.R400Q, in unrelated families with SOD, which substitute highly conserved residues, and have shown that these variants are functionally compromised. These mutant proteins show reduced repressing activity relative to wild-type TCF7L1 using both the TOPflash reporter plasmid and a luciferase reporter containing a fragment of the human LEF1 promoter (Fig. 7) (33) . In addition, we show that the TCF7L1 p.R92P and p.R400Q variants cannot rescue the eye defects of zebrafish mutants with a reduced gene dosage of tcf7l1 (Fig. 8) . Given the presence of the variants in the phenotypically unaffected father and paternal uncle, our data suggest that the variants are not uniquely responsible for disease development but may be variably penetrant. The concept of variable penetrance has been observed in a variety of human genetic disorders. These disorders include Kallmann syndrome, where recent data have suggested an oligogenic basis to the disorder (62) . Additionally, mutations in SHH and GLI2, a mediator of SHH, are associated with variably penetrant holoprosencephaly. Sequence variants in LHX4 and GLI2 are also associated with variably penetrant CH (63, 64) . Of note, variable phenotypic expressivity is also observed in the Hesx1
Cre/+ ;Tcf7l1 fl/− mouse mutants and in the tcf7l1a −/− ;tcf3l1b +/− zebrafish mutants injected with the hTCF7L1 variants identified in this study.
In summary, we identify Tcf7l1 as a determinant for the establishment of the HP axis and as a potential candidate gene to be mutated in congenital hypopituitarism.
